Lung Cancer Clinical Roundup
(IDIBELL [Spain]) Oct 7, 2020 - A study has evaluated the efficacy and safety of the combination of 3 cycles of chemotherapy with immunotherapy (nivolumab) before surgery, in 51 patients with locally advanced lung cancer, followed by one year of treatment with immunotherapy.
(BMS) Oct 7, 2020 - Bristol Myers Squibb today announced that the Phase 3 CheckMate -816 trial met a primary endpoint of pathologic complete response (pCR) in resectable non-small cell lung cancer (NSCLC).
In the trial, significantly more patients treated with Opdivo (nivolumab) plus chemotherapy before surgery showed no evidence of...
(Docwirenews) Oct 5, 2020 - The turn-around time for liquid biopsy is considerably faster than a tissue-based test, according to the findings of a pilot test presented today at the IASLC 2020 Lung Cancer Hot Topic: Liquid Biopsy Virtual Conference.
(Amgen) Oct 5, 2020 - Amgen today announced positive topline Phase 2 results from the CodeBreaK 100 clinical study, evaluating sotorasib (proposed INN for AMG 510) in 126 patients with KRAS G12C-mutant advanced non-small cell lung cancer (NSCLC), who had failed a median of two prior lines of anti-cancer therapies (immunotherapy and/or...
(BMS) Oct 2, 2020 - Opdivo + Yervoy is the first new systemic therapy in over 15 years to be approved by the FDA in this setting. Approval is based on CheckMate -743 in which Opdivo + Yervoy demonstrated superior overall survival vs. standard of care chemotherapy.
Approval marks third indication for Opdivo + Yervoy-based treatments in...
(Journal of clinical oncology : official journal of the American Society of Clinical Oncology) - 2020-10-06
(Clinical cancer research : an official journal of the American Association for Cancer Research) - 2020-10-07
(Cancer research) - 2020-10-07
In a study reported at the European Society of Medical Oncology (ESMO) Virtual Congress 2020 ESMO Meeting, first-line cemiplimab monotherapy significantly improved overall survival (OS) and progression-free (PFS) vs platinum-doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) whose tumors express PD-L1 ≥50%. Despite a high crossover rate, the study provided a rationale for cemiplimab as a new treatment option for this patient population.